Ultragenyx Pharmaceutical Inc.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is dedicated to transforming the lives of people with rare and ultra-rare genetic diseases by developing and delivering innovative treatments where none currently exist. The company focuses on advancing medicines across multiple indications with a robust and diverse clinical pipeline.

Products & Services

DTX401:Therapy for Glycogen Storage Disease Type Ia (GSDIa).

DTX301:Therapy for Ornithine Transcarbamylase (OTC) Deficiency.

UX701:Therapy for Wilson Disease.

UX143:Therapy for Osteogenesis Imperfecta (OI).

GTX-102:Therapy for Angelman Syndrome (AS).

UX111:Therapy for Mucopolysaccharidosis Type IIIA (MPS IIIA).

UX055:Therapy for CDD (specific condition not detailed in content).

Specialties

Rare and Ultra-Rare Genetic Diseases Gene Therapy Drug Development for Genetic Diseases Clinical Trial Transparency Disease Monitoring Programs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: $350 million FAN: 350000000	D: 2024-06-13 FD: 2024-06-13	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: $350,000,000 FAN: 350000000	D: 2024-06-12 FD: 2024-06-12	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 326100000 MR: - FA: 326.1 million FAN: 326100000	D: 2023-10-23 FD: 2023-10-23	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2023-10-18 FD: 2023-10-18	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: up to $300,000,000 FAN: 300000000	D: 2023-10-17 FD: 2023-10-17	4 investors

Public Offering Latest

2024-06-13

$350.0M

4 investors (Pro only)

Public Offering 2024-06-12

$350.0M

Public Offering 2023-10-23

$326.1M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Emil D. Kakkis

Founder, President and Chief Executive Officer, Ultragenyx

LinkedIn (Pro only)

E

Eric Crombez

Chief Medical Officer and Executive Vice President

LinkedIn (Pro only)

E

Erik Harris

Chief Commercial Officer and Executive Vice President

LinkedIn (Pro only)

H

Howard Horn

Chief Financial Officer and Executive Vice President, Corporate Strategy

D

Dennis Huang

Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development

E

Ernie Meyer

Chief Human Resources Officer and Executive Vice President

View 13 more team members with Pro

Unlock Full Team Directory

Recent News